Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179150 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL169110 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| Hydrochloric Acid SCHEMBL3335334 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| Hydrochloric Acid SCHEMBL28608773 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| Hydrochloric Acid SCHEMBL3335329 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL938791 | 0.94 | MEN1 (0.51) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL938782 | 0.94 | MEN1 (0.51) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL19156 | 0.94 | MEN1 (0.51) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL8541058 | 0.92 | MEN1 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| Hydrochloric Acid SCHEMBL1764829 | 0.92 | MEN1 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634178-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| EP-4588920-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-119968371-A | Novel PRMT5 inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025060911-A1 | SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都奥睿药业有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025051157-A1 | PYRIDINE-2(1H)-KETONE PRMT5-MTA INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024126404-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024067445-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-114105887-B | Aminopyrimidine derivative and preparation method and application thereof | 沈阳药科大学 | 2023-12-01 | — | — | CN | disclosed |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-1773821-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | MERCK SHARP & DOHME CORP. | 2006-11-09 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2006015150-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | CYLENE PHARMACEUTICALS (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | CYLENE PHARMACEUTICALS | 2006-02-02 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | PIN1, HPD, DHPS | CHRNB2 4795/4885CHRNA7 4252/4885CHRNA4 4292/4885 |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | RIPK1, RIPK3, RIPK2 | CHRNB2 3758/4885CHRNA7 2486/4885CHRNA4 3557/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CHRNB2 4402/4885CHRNA7 3706/4885CHRNA4 4253/4885 |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | ADAM17, ADAMTS1, ADAM10 | CHRNB2 4451/4885CHRNA7 3805/4885CHRNA4 4168/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | CHRNB2 3593/4885CHRNA7 3022/4885CHRNA4 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.